In addition, potential treatment targets or biomarkers for SCLC, such as MYC, PARP1, SLFN11, CDK7, BCL2, and CD274, were found to be differentially expressed in individual cells, highlighting the need for patient selection to improve targeted therapeutic strategies. This evidence concerns the gene BCL2 and small cell lung carcinoma.